Glucagon antagonists/inverse agonists

1. A compound of formula (I 6 ):

wherein R 46 and R 47 are selected from hydrogen, halogen, —CN, —CF 3 , —OCF 3 , —NO 2 , —OR 10 , —NR 10 R 11 and C 1-6 -alkyl,

wherein R 10 and R 11 independently are hydrogen or C 1-6 -alkyl;

R 1 is hydrogen or C 1-6 -alkyl;

X is

wherein

r is 0 or 1,

q and s independently are 0, 1, 2 or 3,

R 12 , R 13 , R 14 and R 15 independently are hydrogen or C 1-6 -alkyl;

D is

wherein

W is —O—, —S—, —S(O) 2 — or —NR 20 —,

W′ is ═CR 20′ — or ═N—,

R 16 , R 17 , R 18 and R 19 independently are

hydrogen, halogen, —CN, —CH 2 CN, —CHF 2 , —CF 3 , —OCF 3 , —OCHF 2 , —OCH 2 CF 3 , —OCF 2 CHF 2 , —OS(O) 2 CF 3 , —SCF 3 , —NO 2 , —OR 21 , —NR 21 R 22 , —SR 21 , —NR 21 S(O) 2 R 22 , —S(O) 2 NR 21 R 22 , —S(O)NR 21 R 22 , —S(O)R 21 , —S(O) 2 R 21 , —OS(O) 2 R 21 , —C(O)NR 21 R 22 , —OC(O)NR 21 R 22 , —NR 21 C(O)R 22 , —CH 2 C(O)NR 21 R 22 , —OCH 2 C(O)NR 21 R 22 , —CH 2 OR 21 , —CH 2 NR 21 R 22 , —OC(O)R 21 , —C(O)R 21 or —C(O)OR 21 ,

C 1-6 -alkyl, C 2-6 -alkenyl or C 2-6 -alkynyl,

which may optionally be substituted with one or more substituents selected from —CHF 2 , —CF 3 , —OCF 3 , —OCHF 2 , —OCH 2 CF 3 , —OCF 2 CHF 2 , —SCF 3 , —OR 21 , —NR 21 R 22 , —SR 21 , —S(O)R 21 , —S(O) 2 R 21 , —C(O)NR 21 R 22 , —OC(O)NR 21 R 22 , —NR 21 C(O)R 22 , —OCH 2 C(O)NR 21 R 22 , —C(O)R 21 and —C(O)OR 21 ,

C 3-8 -cycloalkyl, C 4-8 -cycloalkenyl, heterocyclyl, C 3-8 -cycloalkyl-C 1-6 -alkyl, C 3-8 -cycloalkyl-C 1-6 -alkoxy, C 3-8 -cycloalkyloxy, C 3-8 -cycloalkyl-C 1-6 -alkylthio, C 3-8 -cycloalkylthio, C 3-8 -cycloalkyl-C 2-6 -alkenyl, C 3-8 -cycloalkyl-C 2-6 -alkynyl, C 4-8 -cycloalkenyl-C 1-6 -alkyl, C 4-8 -cycloalkenyl-C 2-6 -alkenyl, C 4-8 -cycloalkenyl-C 2-6 -alkynyl, heterocyclyl-C 1-6 -alkyl, heterocyclyl-C 2-6 -alkenyl or heterocyclyl-C 2-4 -alkynyl,

of which the cyclic moieties optionally may be substituted with one or more substituents selected from

—CHF 2 , —CF 3 , —OCF 3 , —OCHF 2 , —OCH 2 CF 3 , —OCF 2 CHF 2 , —SCF 3 , —OR 21 , —NR 21 R 22 , —SR 21 , —S(O)R 21 , —S(O) 2 R 21 , —C(O)NR 21 R 22 , —OC(O)NR 21 R 22 , —NR 21 C(O)R 22 , —OCH 2 C(O)NR 21 R 22 , —C(O)R 21 and —C(O)OR 21 ,

C 1-6 -alkyl, C 2-6 -alkenyl and C 2-6 -alkynyl,

which may optionally be substituted with one or more substituents selected from —CHF 2 , —CF 3 , —OCF 3 , —OCHF 2 , —OCH 2 CF 3 , —OCF 2 CHF 2 , —SCF 3 , —OR 21 , —NR 21 R 22 , —SR 21 , —S(O)R 21 , —S(O) 2 R 21 , —C(O)NR 21 R 22 , —OC(O)NR 21 R 22 , —NR 21 C(O)R 22 , —OCH 2 C(O)NR 21 R 22 , —C(O)R 21 and —C(O)OR 21 ,

aryl, aryloxy, aryloxycarbonyl, aroyl, aryl-C 1-6 -alkoxy, aryl-C 1-6 -alkyl, aryl-C 2-6 -alkenyl, aryl-C 2-6 -alkynyl, heteroaryl, heteroaryl-C 1-6 -alkyl, heteroaryl-C 2-6 -alkenyl or heteroaryl-C 2-6 -alkynyl,

of which the aryl and heteroaryl moieties optionally may be substituted with one or more substituents selected from

halogen, —CN, —CH 2 CN, —CHF 2 , —CF 3 , —OCF 3 , —OCHF 2 , —OCH 2 CF 3 , —OCF 2 CHF 2 , —OS(O) 2 CF 3 , —SCF 3 , —NO 2 , —OR 21 , —NR 21 R 22 , —SR 21 , —NR 21 S(O) 2 R 22 , —S(O) 2 NR 21 R 22 , —S(O)NR 21 R 22 , —S(O)R 21 , —S(O) 2 R 21 , —OS(O) 2 R 21 , —C(O)NR 21 R 22 , —OC(O)NR 21 R 22 , —NR 21 C(O)R 22 , —CH 2 C(O)NR 21 R 22 , —OCH 2 C(O)NR 21 R 22 , —CH 2 OR 21 , —CH 2 NR 21 R 22 , —OC(O)R 21 , —C(O)R 21 and —C(O)OR 21 ,

C 1-6 -alkyl, C 2-6 -alkenyl and C 2-6 -alkynyl,

which may optionally be substituted with one or more substituents selected from —CHF 2 , —CF 3 , —OCF 3 , —OCHF 2 , —OCH 2 CF 3 , —OCF 2 CHF 2 , —SCF 3 , —OR 21 , —NR 21 R 22 , —SR 21 , —S(O)R 21 , —S(O) 2 R 21 , —C(O)NR 21 R 22 , —OC(O)NR 21 R 22 , —NR 21 C(O)R 22 , —OCH 2 C(O)NR 21 R 22 , —C(O)R 21 and —C(O)OR 21 ,

wherein R 21 and R 22 independently are hydrogen, —CF 3 , C 1-6 -alkyl, tri-C 1-6 -alkylsilyl, C 3-8 -cycloalkyl, C 3-8 -cycloalkyl-C 1-6 -alkyl, aryl, aryl-C 1-6 -alkyl or heteroaryl,

or R 21 and R 22 when attached to the same nitrogen atom together with the said nitrogen atom may form a 3 to 8 membered heterocyclic ring optionally containing one or two further heteroatoms selected from nitrogen, oxygen and sulfur, and optionally containing one or two double bonds, or two of the groups R 16 to R 19 when placed in adjacent positions together may form a bridge —(CR 16′ R 17′ ) a —O—(CR 18′ R 19′ ) c —O—,

wherein

a is 0, 1 or 2,

c is 1 or 2,

R 16′ , R 17′ , R 18′ and R 19 ′ independently are hydrogen, C 1-6 -alkyl or halogen,

R 20 and R 20′ independently are hydrogen, C 1-6 -alkyl, C 3-8 -cycloalkyl or C 3-8 -cycloalkyl-C 1-6 -alkyl;

E is a 3 to 9 membered mono- or bicyclic ring which may optionally contain one or two double bonds and which may optionally contain one or two heteroatoms selected from nitrogen, oxygen and sulfur, wherein one or two groups R 23 and R 24 may be attached to the same or different ring carbon atoms and wherein a group R 31 may be attached to a ring nitrogen atom when present, or

wherein

m and p independently are 0, 1, 2, 3 or 4, with the proviso that when both m and p are present in the same formula at least one of m and p is different from 0,

R 23 and R 24 independently are

hydrogen, —CHF 2 , —CF 3 , —OCF 3 , —OCHF 2 , —OCH 2 CF 3 , —OCF 2 CHF 2 , —SCF 3 , —OR 36 , —NR 36 R 37 , —SR 36 , —S(O)R 36 , —S(O) 2 R 36 , —C(O)NR 36 R 37 , —OC(O)NR 36 R 37 , —NR 36 C(O)R 37 , —OCH 2 C(O)NR 36 R 37 , —C(O)R 36 or —C(O)OR 36 ,

C 1-6 -alkyl, C 2-6 -alkenyl or C 2-6 -alkynyl,

which may optionally be substituted with one or more substituents selected from —CHF 2 , —CF 3 , —OCF 3 , —OCHF 2 , —OCH 2 CF 3 , —OCF 2 CHF 2 , —SCF 3 , —OR 36 , —NR 36 R 37 , —SR 36 , —S(O)R 36 , —S(O) 2 R 36 , —C(O)NR 36 R 37 , —OC(O)NR 36 R 37 , —NR 36 C(O)R 37 , —OCH 2 C(O)NR 36 R 37 , —C(O)R 36 and —C(O)OR 36 ,

C 3-8 -cycloalkyl, C 3-8 -cycloalkylidene, C 4-8 -cycloalkenyl, heterocyclyl, C 3-8 -cycloalkyl-C 1-6 -alkyl, C 3-8 -cycloalkyl-C 2-6 -alkenyl, C 3-8 -cycloalkyl-C 2-6 -alkynyl, C 4-8 -cycloalkenyl-C 1-6 -alkyl, C 4-8 -cycloalkenyl-C 2-6 -alkenyl, C 4-8 -cycloalkenyl-C 2-6 -alkynyl, heterocyclyl-C 1-6 -alkyl, heterocyclyl-C 2-6 -alkenyl or heterocyclyl-C 2-6 -alkynyl,

of which the cyclic moieties optionally may be substituted with one or more substituents selected from

—CHF 2 , —CF 3 , —OCF 3 , —OCHF 2 , —OCH 2 CF 3 , —OCF 2 CHF 2 , —SCF 3 , —OR 36 , —NR 36 R 37 , —SR 36 , —S(O)R 36 , S(O) 2 R 36 , C(O)NR 36 R 37 , —OC(O)NR 36 R 37 , —NR 36 C(O)R 37 , —OCH 2 C(O)NR 36 R 37 , —C(O)R 36 and —C(O)OR 36 ,

C 1-6 -alkyl, C 2-6 -alkenyl and C 2-6 -alkynyl,

which may optionally be substituted with one or more substituents selected from —CHF 2 , —CF 3 , —OCF 3 , —OCHF 2 , —OCH 2 CF 3 , —OCF 2 CHF 2 , —SCF 3 , —OR 36 , —NR 36 R 37 , —SR 36 , —S(O)R 36 , —S(O) 2 R 36 , —C(O)NR 36 R 37 ,

—OC(O)NR 36 R 37 , —NR 36 C(O)R 37 , —OCH 2 C(O)NR 36 R 37 , —C(O)R 36 and —C(O)OR 36 ,

aryl, aryloxy, aroyl, aryl-C 1-6 -alkoxy, aryl-C 1-6 -alkyl, aryl-C 2-6 -alkenyl, aryl-C 2-6 -alkynyl, heteroaryl, heteroaryl-C 1-6 -alkyl, heteroaryl-C 2-6 -alkenyl or heteroaryl-C 2-6 -alkynyl,

of which the aryl and heteroaryl moieties optionally may be substituted with one or more substituents selected from

halogen, —CN, —CH 2 CN, —CHF 2 , —CF 3 , —OCF 3 , —OCHF 2 , —OCH 2 CF 3 , —OCF 2 CHF 2 , —OS(O) 2 CF 3 , —SCF 3 , —NO 2 , —OR 36 , —NR 36 R 37 , —SR 36 —NR 36 S(O) 2 R 37 , —S(O) 2 NR 36 R 37 , —S(O)NR 36 R 37 , —S(O)R 36 , —S(O) 2 R 36 , —OS(O) 2 R 36 , —C(O)NR 36 R 37 , —OC(O)NR 36 R 37 , —NR 36 C(O)R 37 , —CH 2 C(O)NR 36 R 37 , —CH 2 C(O)NR 36 R 37 , —CH 2 OR 36 , —CH 2 NR 36 R 37 , —OC(O)R 36 , —C(O)R 36 and —C(O)OR 36 ,

C 1-6 -alkyl, C 2-6 -alkenyl and C 2-6 -alkynyl,

which may optionally be substituted with one or more substituents selected from —CHF 2 , —CF 3 , —OCF 3 , —OCHF 2 , —OCH 2 CF 3 , —OCF 2 CHF 2 , —SCF 3 , —OR 36 , —NR 36 R 37 , —SR 36 , —S(O)R 36 , —S(O) 2 R 36 , —C(O)NR 36 R 37 , —OC(O)NR 36 R 37 , —NR 36 C(O)R 37 , —OCH 2 C(O)NR 36 R 37 , —C(O)R 36 and —C(O)OR 36 ,

wherein R 36 and R 37 independently are hydrogen, C 1-6 -alkyl or aryl,

of which the aryl moiety optionally may be substituted with one or more substituents selected from halogen, —CN, —CF 3 , —OCF 3 , —NO 2 , —OR 38 , —NR 38 R 39 and C 1-6 -alkyl,

wherein R 38 and R 39 independently are hydrogen or C 1-6 -alkyl,

or R 36 and R 37 when attached to the same nitrogen atom together with the said nitrogen atom may form a 3 to 8 membered heterocyclic ring optionally containing one or two further heteroatoms selected from nitrogen, oxygen and sulfur, and optionally containing one or two double bonds,

or R 23 and R 24 when attached to the same ring carbon atom or different ring carbon atoms together may form a radical —O—(CH 2 ) t —CR 40 R 41 —(CH 2 ) l —O—, —(CH 2 ) t —CR 40 R 41 —(CH 2 ) l — or —S—(CH 2 ) t —CR 40 R 41 —(CH 2 ) l —S—,

wherein

t and l independently are 0, 1, 2, 3, 4 or 5,

R 40 and R 41 independently are hydrogen or C 1-6 -alkyl,

R 25 to R 30 independently are hydrogen, halogen, —CN, —CF 3 , —NO 2 , —OR 42 , —NR 42 R 43 , C 1-6 -alkyl, C 3-8 -cycloalkyl or C 4-8 -cycloalkenyl,

wherein R 42 and R 43 independently are hydrogen or C 1-6 -alkyl, or

R 42 and R 43 when attached to the same nitrogen atom together with the said nitrogen atom may form a 3 to 8 membered heterocyclic ring optionally containing one or two further heteroatoms selected from nitrogen, oxygen and sulfur, and optionally containing one or two double bonds,

R 31 , R 32 and R 33 independently are hydrogen or C 1-6 -alkyl,

R 34 and R 35 independently are

hydrogen, C 1-6 -alkyl, C 1-6 -alkoxy, C 1-6 -alkanoyl, —C(O)NR 44 R 45 or —S(O) 2 R 45 ,

aryl, aroyl, aryl-C 1-6 -alkoxy, aryl-C 1-6 -alkanoyl or aryl-C 1-6 -alkyl,

of which the aryl moieties optionally may be substituted with one or more substituents selected from halogen, —CN, —CF 3 , —OCF 3 , —OR 44 , —NR 44 R 45 and C 1-6 -alkyl,

wherein R 44 and R 45 independently are hydrogen or C 1-6 -alkyl, or

R 34 and R 35 when attached to a carbon atom together with the said carbon atom may form a 3 to 8 membered cyclic ring optionally containing one or two heteroatoms selected from nitrogen, oxygen or sulfur, and optionally containing one or two double bonds, or

R 34 and R 35 when attached to a nitrogen atom together with the said nitrogen atom may form a 3 to 8 membered heterocyclic ring optionally containing one or two further heteroatoms selected from nitrogen, oxygen or sulfur, and optionally containing one or two double bonds,

as well as any optical or geometric isomer or tautomeric form thereof including mixtures of these or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 , wherein R 46 and R 47 are hydrogen.

3. A compound according to claim 1 , wherein R 1 is hydrogen.

4. A compound according to claim 1 , wherein R 1 is methyl.

5. A compound according to claims 1 , wherein X is

6. A compound according to claim 5 , wherein X is

wherein q is 0 or 1, r is 0 or 1, s is 0, 1 or 2, and R 13 is hydrogen or C 1-6 -alkyl.

7. A compound according to claim 6 , wherein X is —C(O)NH—, —C(O)NHCH 2 —, —C(O)NHCH(CH 3 )—, —C(O)NHCH 2 CH 2 —, —C(O)CH 2 —, —C(O)CH═CH—, —(CH 2 ) s —, —C(O)—, —C(O)O— or —NHC(O)—, wherein s is 0 or 1.

8. A compound according to claim 7 , wherein X is —C(O)NH—, —C(O)NHCH 2 —, —C(O)NHCH(CH 3 )—, —C(O)NHCH 2 CH 2 —, —C(O)CH 2 —, —CH 2 —, —C(O)— or —NHC(O)—.

9. A compound according to claim 8 , wherein X is —C(O)NH—.

10. A compound according to claim 9 , wherein X is —C(O)NHCH(CH 3 )—.

11. A compound according to claim 1 , wherein D is

12. A compound according to claim 11 , wherein D is

13. A compound according to claim 12 , wherein D is

14. A compound according to claim 13 , wherein R 16 and R 17 are both hydrogen and R 20 is C 1-6 -alkyl or C 3-8 -cycloalkyl-C 1-6 -alkyl.

15. A compound according to claim 13 , wherein R 20 is cyclopropylmethyl, butyl or isopropyl.

16. A compound according to claim 15 , wherein R 20 is isopropyl.

17. A compound according to claim 12 , wherein D is

18. A compound according to claim 12 , wherein D is

19. A compound according to claim 11 , wherein R 16 , R 17 and R 18 independently are

hydrogen, halogen, —CN, —NO 2 , —CF 3 , —OCF 3 , hydroxy, —SCF 3 , C 1-6 -alkyl, C 1-6 -alkyl substituted with hydroxy, C 1-6 -alkyl substituted with —S(O) 2 R 21 , C 1-6 -alkoxy, —S—C 1-6 -alkyl, —C(O)OR 21 , —C(O)R 21 , —CH 2 (O)R 21 , —C(O)NR 21 R 22 , —S(O)R 21 , —S(O) 2 R 21 , —S(O) 2 CF 3 , —S(O) 2 NR 21 R 22 , C 3-8 -cycloalkyl, C 3-8 -cycloalkyl-C 1-6 -alkoxy, C 3-8 -cycloalkyl-C 1-6 -alkylthio or C 3-8 -cycloalkylthio,

wherein R 21 and R 22 independently are hydrogen, C 1-6 -alkyl, tri-C 1-6 -alkylsilyl, C 3-8 -cycloalkyl, C 3-8 -cycloalkyl-C 1-6 -alkyl, phenyl, phenyl-C 1-6 -alkyl, 2,3-dihydroindolyl or isoindolyl, or R 21 and R 22 together with the nitrogen atom to which they are attached form a piperidine ring,

phenoxy, phenoxycarbonyl, phenyl, phenyl-C 1-6 -alkoxy, phenyl-C 1-6 -alkyl, furanyl, tetrazolyl, benzoxazolyl or oxadiazolyl, of which the ring systems optionally may be substituted with halogen, —CN, —CF 3 , —OCF 3 , —NO 2 , —C(O)OR 21 , —OR 21 , —NR 21 R 22 or C 1-6 -alkyl, wherein R 21 and R 22 independently are hydrogen or C 1-6 -alkyl, or

wherein R 16 and R 17 in adjacent positions form the radical —O—CH 2 —O—, —CF 2 —O—CF 2 —O— or —O—CF 2 —CF 2 —O—, and R 18 is hydrogen.

20. A compound according to claim 19 , wherein R 16 , R 17 and R 18 independently are

hydrogen, halogen, —CN, —NO 2 , —CF 3 , —OCF 3 , —SCF 3 , C 1-6 -alkyl, C 1-6 -alkyl substituted with hydroxy, C 1-6 -alkyl substituted with —S(O) 2 R 21 , C 1-6 -alkoxy, —S—C 1-6 -alkyl, —C(O)OR 21 , —C(O)R 21 , —CH 2 (O)R 21 , —C(O)NR 21 R 22 , —S(O)R 21 , —S(O) 2 R 21 , —S(O) 2 CF 3 , —S(O) 2 NR 21 R 22 , C 3-8 -cycloalkyl-C 1-6 -alkoxy, C 3-8 -cycloalkyl-C 1-6 -alkylthio or C 3-8 -cycloalkylthio,

wherein R 21 and R 22 independently are hydrogen, C 1-6 -alkyl, tri-C 1-6 -alkylsilyl, C 3-8 -cycloalkyl, C 3-8 -cycloalkyl-C 1-6 -alkyl, phenyl or 2,3-dihydroindolyl, or R 21 and R 22 together with the nitrogen atom to which they are attached form a piperidine ring,

phenoxy, phenyl, benzyl, furanyl, tetrazolyl, benzoxazolyl or oxadiazolyl, of which the ring systems optionally may be substituted with halogen, —C(O)OR 21 or C 1-6 -alkyl, wherein R 21 is hydrogen or C 1-6 -alkyl, or

wherein R 16 and R 17 in adjacent positions form the radical —CF 2 —O—CF 2 —O— or —O—CF 2 —CF 2 —O—, and R 18 is hydrogen.

21. A compound according to claim 20 , wherein R 16 , R 17 and R 18 independently are

hydrogen, halogen, —CN, —NO 2 , —CF 3 , —OCF 3 , —SCF 3 , C 1-6 -alkyl, C 1-6 -alkyl substituted with hydroxy, C 1-6 -alkoxy, —S—C 1-6 -alkyl, —C(O)OR 21 , —C(O)R 21 , —CH 2 (O)R 21 , —C(O)NR 21 R 22 , —S(O) 2 R 21 , —(O) 2 CF 3 or —S(O) 2 N R 21 R 22 ,

wherein R 21 and R 22 independently are hydrogen, C 1-6 -alkyl, tri-C 1-6 -alkylsilyl, phenyl or 2,3-dihydroindolyl,

phenoxy, phenyl, benzyl, furanyl, tetrazolyl, benzoxazolyl or oxadiazolyl, of which the ring systems optionally may be substituted with halogen, —C(O)OR 21 or C 1-6 -alkyl, wherein R 21 is hydrogen or C 1-6 -alkyl, or

wherein R 16 and R 17 in adjacent positions form the radical —CF 2 —O—CF 2 —O— or —O—CF 2 —CF 2 —O—, and R 18 is hydrogen.

22. A compound according to claim 21 , wherein R 16 , R 17 and R 18 independently are hydrogen, halogen, —CN, —NO 2 , —CF 3 , —OCF 3 , —SCF 3 , C 1-6 -alkyl, C 1-6 -alkoxy, —S—C 1-6 -alkyl, —C(O)OC 1-6 -alkyl, —S(O) 2 C 1-6 -alkyl, —S(O) 2 CF 3 , —C(O)N(C 1-6 -alkyl)(C 1-6 -alkyl), —S(O) 2 N(phenyl)(C 1-6 -alkyl), —C(═O)C 1-6 -alkyl, —CH 2 OH, —CH 2 O(tri-C 1-6 -alkylsilyl), 2,3-dihydro-indol-1-ylsulfonyl, phenoxy, phenyl, 4-chlorophenyl, 1,3,5-trimethylbenzyl, benzoxazolyl, 2-methyltetrazol-5-yl, 2-methyl-3-methoxycarbonylfuran-5-yl or 3-isopropyl-[1,2,4]oxadiazol-5-yl).

23. A compound according to claim 19 , wherein one of R 16 to R 18 is hydrogen.

24. A compound according to claim 19 , wherein two of R 16 to R 18 are hydrogen.

25. A compound according to claim 19 , wherein R 16 and R 17 are both hydrogen and R 18 is —OCF 3 , —SCF 3 —CF 3 , —S(O) 2 CH 3 , phenyl, halogen, C 1-6 -alkyl, nitro, —S—C 1-6 -alkyl or —S(O) 2 NR 21 R 22 , wherein R 21 is C 1-6 -alkyl and R 22 is phenyl.

26. A compound according to claim 19 , wherein R 16 and R 17 are both hydrogen and R 18 is —OCF 3 or halogen.

27. A compound according to claim 19 , wherein R 16 is hydrogen and R 17 and R 18 are both halogen or are both —CF 3 .

28. A compound according to claim 19 , wherein R 16 is hydrogen, R 17 is —CF 3 and R 18 is halogen, —CN, C 1-6 -alkoxy or —OCF 3 .

29. A compound according to claim 19 , wherein R 16 is hydrogen, R 17 is —OCF 3 and R 18 is —S(O) 2 CH 3 , —CH 2 O-tri-C 1-6 -alkylsilyl, benzoxazolyl or —CH 2 OH.

30. A compound according to claim 19 , wherein R 16 is hydrogen, R 17 is C 1-6 -alkyl and R 18 is —S(O) 2 NR 21 R 22 , wherein R 21 is C 1-6 -alkyl and R 22 is phenyl.

31. A compound according to claim 19 , wherein R 16 , R 17 and R 18 are selected from hydrogen, —OCF 3 , —CF 3 , —Br, —F and —Cl.

32. A compound according to claim 1 , wherein E is

33. A compound according to claim 32 , wherein E is

34. A compound according to claim 33 , wherein E is

35. A compound according to claim 34 , wherein E is

36. A compound according to claim 35 , wherein R 34 and R 35 independently are C 1-6 -alkyl, hydrogen or C 1-6 -alkoxy.

37. A compound according to claim 36 , wherein R 34 and R 35 are both C 1-6 -alkyl.

38. A compound according to claim 37 , wherein E is

39. A compound according to claim 38 , wherein E is

40. A compound according to claim 38 , wherein R 23 and R 24 independently are selected from hydrogen, C 1-6 -alkyl, C 3-8 -cycloalkyl, C 3-8 -cycloalkylidene, phenoxy, phenyl, —C(O)NR 36 R 37 and —OC(O)NH-phenyl, of which the phenyl moiety optionally may be substituted with —OCF 3 , or R 23 and R 24 together form the radical —(CH 2 ) t —CR 40 R 41 —(CH 2 ) l —, —O—(CH 2 ) t —CR 40 R 41 —(CH 2 ) l —O—, —S—(CH 2 ) t —CR 40 R 41 —(CH 2 ) l —S—.

41. A compound according to claim 40 , wherein R 23 is hydrogen and R 24 is C 1-6 -alkyl such as tert-butyl or C 3-8 -cycloalkyl such as cyclohexyl, wherein R 23 and R 24 are both C 1-6 -alkyl or wherein R 23 and R 24 together form the radical —(CH 2 ) 5 —.

42. A compound according to claim 35 , wherein E is

43. A compound according to claim 42 , wherein E is

44. A compound according to claim 42 , wherein R 25 , R 26 and R 27 independently are selected from hydrogen, halogen, C 1-6 -alkyl, C 1-6 -alkoxy, C 3-8 -cycloalkyl, C 4-8 -cycloalkenyl, —CF 3 , —OCF 3 or —NR 42 R 43 , wherein R 42 and R 43 are as defined in claim 1 .

45. A compound according to claim 44 , wherein E is

wherein R 25 is —OCF 3 , —CF 3 , C 1-6 -alkyl such as tert-butyl, piperidyl, C 3-8 -cycloalkyl such as cyclohexyl or C 4-8 -cycloalkenyl such as cyclohexenyl.

46. A compound according to claim 45 , wherein E is

47. A compound according to claim 46 , wherein E is

48. A compound according to claim 1 , which has an IC 50 value of no greater than 5 μM as determined by Glucagon Binding Assay (I), Glucagon Binding Assay (II) or Glucagon Binding Assay (III).

49. A compound according to claim 48 , characterized by having a glucagon antagonistic activity as determined by Glucagon Binding Assay (I), Glucagon Binding Assay (II) or Glucagon Binding Assay (III) corresponding to an IC 50 value of less than 1 μM.

50. A compound according to claim 48 characterized by having a glucagon antagonistic activity as determined by Glucagon Binding Assay (I), Glucagon Binding Assay (II) or Glucagon Binding Assay (III) corresponding to an IC 50 value of less than 500 nM.

51. A compound according to claim 48 characterized by having a glucagon antagonistic activity as determined by Glucagon Binding Assay (I), Glucagon Binding Assay (II) or Glucagon Binding Assay (III) corresponding to an IC 50 value of less than 100 nM.

52. A compound according to claim 1 , which is an agent useful for the treatment and/or prevention of an indication selected from the group consisting of hyperglycemia, impaired glucose tolerance, Type 2 diabetes, Type 1 diabetes and obesity.

53. A pharmaceutical composition comprising, as an active ingredient, at least one compound according to claim 1 together with one or more pharmaceutically acceptable carriers or excipients.

54. A pharmaceutical composition according to claim 53 in unit dosage form, said composition comprising from about 0.05 mg to about 1000 mg of said compound.

55. A pharmaceutical composition according to claim 53 in unit dosage form, said composition comprising from about 0.1 mg to about 500 mg of said compound.

56. A pharmaceutical composition according to claim 53 in unit dosage form, said composition comprising from about 0.5 mg to about 200 mg of said compound.

57. A method for the treatment of disorders or diseases mediated by a glucagon antagonistic action, said method comprising administering to a subject in need thereof an effective amount of a compound according to claim 1 .

58. The method according to claim 57 , wherein the effective amount of the compound is in the range of from about 0.05 mg to about 2000 mg per day.

59. The method according to claim 57 , wherein the effective amount of the compound is in the range of from about 0.1 mg to about 1000 mg per day.

60. The method according to claim 57 , wherein the effective amount of the compound is in the range of from about 0.5 mg to about 500 mg per day.

61. The method of claim 57 , wherein the disorder or disease is selected from the group consisting of hyperglycemia, impaired glucose tolerance (IGT), Type 2 diabetes and Type 1 diabetes.

62. The method of claim 61 , wherein said method further comprises administering to said subject an antidiabetic agent.

63. The method of claim 57 , wherein the disorder or disease is obesity.

64. The method of claim 63 , wherein said method further comprises administering to said subject an antiobesity agent.

65. A method for lowering blood glucose in a mammal, said method comprising administering to a mammal in need thereof an effective amount of a compound according to claim 1 .

66. A method for delaying the progression from impaired glucose tolerance to Type 2 diabetes in a subject, said method comprising administering to said subject an effective amount of a compound according to claim 1 .

67. A method for delaying the progression from non-insulin requiring Type 2 diabetes to insulin-requiring Type 2 diabetes in a subject, said method comprising administering to said subject an effective amount of a compound according to claim 1 .

68. A compound according to claim 18 , wherein R 16 , R 17 and R 18 independently are hydrogen, halogen, —CN, —NO 2 , —CF 3 , —OCF 3 , hydroxy, —SCF 3 , C 1-6 -alkyl, C 1-6 -alkyl substituted with hydroxy, C 1-6 -alkyl substituted with —S(O) 2 R 21 , C 1-6 -alkoxy, —S—C 1-6 -alkyl, —C(O)OR 21 , —C(O)R 21 , —CH 2 (O)R 21 , —C(O)NR 21 R 22 , —S(O)R 21 , —S(O) 2 R 21 , —S(O) 2 CF 3 , —S(O) 2 NR 21 R 22 , C 3-8 -cycloalkyl, C 3-8 -cycloalkyl-C 1-6 -alkoxy, C 3-8 -cycloalkyl-C 1-6 -alkylthio or C 3-8 -cycloalkylthio,

wherein R 21 and R 22 independently are hydrogen, C 1-6 -alkyl, tri-C 1-6 -alkylsilyl, C 3-8 -cycloalkyl, C 3-8 -cycloalkyl-C 1-6 -alkyl, phenyl, phenyl-C 1-6 -alkyl, 2,3-dihydroindolyl or isoindolyl, or R 21 and R 22 together with the nitrogen atom to which they are attached form a piperidine ring,

phenoxy, phenoxycarbonyl, phenyl, phenyl-C 1-6 -alkoxy, phenyl-C 1-6 -alkyl, furanyl, tetrazolyl, benzoxazolyl or oxadiazolyl, of which the ring systems optionally may be substituted with halogen, —CN, —CF 3 , —OCF 3 , —NO 2 , —C(O)OR 21 , —OR 21 , —NR 21 R 22 or C 1-6 -alkyl, wherein R 21 and R 22 independently are hydrogen or C 1-6 -alkyl, or

wherein R 16 and R 17 in adjacent positions form the radical —O—CH 2 —O—, —CF 2 —O—CF 2 —O— or —O—CF 2 —CF 2 —O—, and R 18 is hydrogen.

69. A compound according to claim 68 , wherein R 16 , R 17 and R 18 independently are

hydrogen, halogen, —CN, —NO 2 , —CF 3 , —OCF 3 , —SCF 3 , C 1-6 -alkyl, C 1-6 -alkyl substituted with hydroxy, C 1-6 -alkyl substituted with —S(O) 2 R 21 , C 1-6 -alkoxy, —S—C 1-6 -alkyl, —C(O)OR 21 , —C(O)R 21 , —CH 2 (O)R 21 , —C(O)NR 21 R 22 , —S(O)R 21 , —S(O) 2 R 21 , —S(O) 2 CF 3 , —S(O) 2 NR 21 R 22 , C 3-8 -cycloalkyl-C 1-6 -alkoxy, C 3-8 -cycloalkyl-C 1-6 -alkylthio or C 3-8 -cycloalkylthio,

wherein R 21 and R 22 independently are hydrogen, C 1-6 -alkyl, tri-C 1-6 -alkylsilyl, C 3-8 -cycloalkyl, C 3-8 -cycloalkyl-C 1-6 -alkyl, phenyl or 2,3-dihydroindolyl, or R 21 and R 22 together with the nitrogen atom to which they are attached form a piperidine ring,

phenoxy, phenyl, benzyl, furanyl, tetrazolyl, benzoxazolyl or oxadiazolyl, of which the ring systems optionally may be substituted with halogen, —C(O)OR 21 or C 1-6 -alkyl, wherein R 21 is hydrogen or C 1-6 -alkyl, or

wherein R 16 and R 17 in adjacent positions form the radical —CF 2 —O—CF 2 —O— or —O—CF 2 —CF 2 —O—, and R 18 is hydrogen.

70. A compound according to claim 69 , wherein R 16 , R 17 and R 18 independently are

hydrogen, halogen, —CN, —NO 2 , —CF 3 , —OCF 3 , —SCF 3 , C 1-6 -alkyl, C 1-6 -alkyl substituted with hydroxy, C 1-6 -alkoxy, —S—C 1-6 -alkyl, —C(O)OR 21 , —C(O)R 21 , —CH 2 (O)R 21 , —C(O)NR 21 R 22 , —S(O)R 21 , —(O) 2 R 21 , or —S(O) 2 R 21 22 ,

wherein R 21 and R 22 independently are hydrogen, C 1-6 -alkyl, tri-C 1-6 -alkylsilyl, phenyl or 2,3-dihydroindolyl,

phenoxy, phenyl, benzyl, furanyl, tetrazolyl, benzoxazolyl or oxadiazolyl, of which the ring systems optionally may be substituted with halogen, —C(O)OR 21 or C 1-6 -alkyl, wherein R 21 is hydrogen or C 1-6 -alkyl, or

wherein R 16 and R 17 in adjacent positions form the radical —CF 2 —O—CF 2 —O— or —O—CF 2 —CF 2 —O—, and R 18 is hydrogen.

71. A compound according to claim 70 , wherein R 16 , R 17 and R 18 independently are hydrogen, halogen, —CN, —NO 2 , —CF 3 , —OCF 3 , —SCF 3 , C 1-6 -alkyl, C 1-6 -alkoxy, —S—C 1-6 -alkyl, —C(O)OC 1-6 -alkyl, —S(O) 2 C 1-6 -alkyl, —S(O) 2 CF 3 , —C(O)N(C 1-6 -alkyl)(C 1-6 -alkyl), —S(O) 2 N(phenyl)(C 1-6 -alkyl), —C(═O)C 1-6 -alkyl, —CH 2 OH, —CH 2 O(tri-C 1-6 -alkylsilyl), 2,3-dihydro-indol-1-ylsulfonyl, phenoxy, phenyl, 4-chlorophenyl, 1,3,5-trimethylbenzyl, benzoxazolyl, 2-methyltetrazol-5-yl, 2-methyl-3-methoxycarbonylfuran-5-yl or 3-isopropyl-[1,2,4]oxadiazol-5-yl).

72. A compound according to claim 68 , wherein one of R 16 to R 18 is hydrogen.

73. A compound according to claim 68 , wherein two of R 16 to R 18 are hydrogen.

74. A compound according to claim 68 , wherein R 16 and R 17 are both hydrogen and R 18 is —OCF 3 , —SCF 3 —CF 3 , —S(O) 2 CH 3 , phenyl, halogen, C 1-6 -alkyl, nitro, —S—C 1-6 -alkyl or —S(O) 2 NR 21 R 22 , wherein R 21 is C 1-6 -alkyl and R 22 is phenyl.

75. A compound according to claim 68 , wherein R 16 and R 17 are both hydrogen and R 18 is —OCF 3 or halogen.

76. A compound according to claim 68 , wherein R 16 is hydrogen and R 17 and R 18 are both halogen or are both —CF 3 .

77. A compound according to claim 68 , wherein R 16 is hydrogen, R 17 is —CF 3 and R 18 is halogen, —CN, C 1-6 -alkoxy or —OCF 3 .

78. A compound according to claim 68 , wherein R 16 is hydrogen, R 17 is —OCF 3 and R 18 is —S(O) 2 CH 3 , —CH 2 O-tri-C 1-6 -alkylsilyl, benzoxazolyl or —CH 2 OH.

79. A compound according to claim 68 , wherein R 16 is hydrogen, R 17 is C 1-6 -alkyl and R 18 is —S(O) 2 NR 21 R 22 , wherein R 21 is C 1-6 -alkyl and R 22 is phenyl.

80. A compound according to claim 68 , wherein R 16 , R 17 and R 18 are selected from hydrogen, —OCF 3 , —CF 3 , —Br, —F and —Cl.